USA – Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients

Regeneron announced today that its antibody cocktail REGEN-COV can be used as a passive vaccine to prevent COVID-19 in people who are at high risk of infection.

The ongoing phase 3 trial is evaluating the cocktail, which contains the two monoclonal antibodies casirivimab and imdevimab, for the prevention of COVID-19 in high-risk populations.

The first exploratory analysis of 400 evaluable participants found that passive vaccination with REGEN-COV resulted in 100% prevention of symptomatic COVID-19 infections.

On top of that, the cocktail led to approximately 50% lower overall rates of infection – with infections occurring with REGEN-COV therapy all being asymptomatic.

Regeneron added that the infections observed in the placebo group had more than 100-fold higher peak viral loads compared to REGEN-COV-treated patients…